Key Points
- Major shareholder Eliyahou Et Al Harari purchased 1,757,469 CapsoVision shares at an average price of $5.69, for approximately $10 million. The transaction was disclosed in an SEC filing.
- CapsoVision opened at $6.05, with a market capitalization of about $302.8 million, a 12-month trading range of $4.34 to $15.37, and continued unprofitable results, including a quarterly loss of $0.15 per share.
- Analyst views remain mixed, resulting in a consensus “Hold” rating and an average price target of $9.50; meanwhile, BlackRock and several other institutions recently established positions in the company.
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) major shareholder Eliyahou Et Al Harari bought 1,757,469 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average price of $5.69 per share, with a total value of $9,999,998.61. Following the transaction, the insider directly owned 1,396,494 shares in the company, valued at $7,946,050.86. This represents a -486.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Eliyahou Et Al Harari also recently made the following trade(s):
- On Friday, July 17th, Eliyahou Et Al Harari purchased 61,068 shares of CapsoVision stock. The shares were bought at an average price of $6.73 per share, for a total transaction of $410,987.64.
- On Wednesday, July 8th, Eliyahou Et Al Harari purchased 81,300 shares of CapsoVision stock. The stock was bought at an average cost of $6.09 per share, with a total value of $495,117.00.
- On Friday, June 26th, Eliyahou Et Al Harari acquired 13,850 shares of CapsoVision stock. The stock was bought at an average price of $7.35 per share, with a total value of $101,797.50.
CapsoVision Price Performance
NASDAQ CV opened at $6.05 on Thursday. CapsoVision, Inc. has a 12 month low of $4.34 and a 12 month high of $15.37. The firm has a market capitalization of $302.78 million, a PE ratio of -12.87 and a beta of -2.47. The company's 50 day simple moving average is $6.41 and its 200 day simple moving average is $6.55.
CapsoVision (NASDAQ:CV - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $3.64 million for the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%. Sell-side analysts anticipate that CapsoVision, Inc. will post -0.56 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on CV. Roth Capital initiated coverage on CapsoVision in a report on Friday, August 28th. They issued a "buy" rating and a $9.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CapsoVision in a report on Monday, June 29th. Zacks Research upgraded shares of CapsoVision to a "hold" rating in a research report on Monday, August 31st. Finally, Benchmark reissued a "speculative buy" rating on shares of CapsoVision in a report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $9.50.
Get Our Latest Stock Analysis on CapsoVision
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of CapsoVision in the second quarter valued at $14,372,000. Bank of New York Mellon Corp bought a new stake in shares of CapsoVision during the 2nd quarter worth $569,000. Deutsche Bank AG acquired a new position in shares of CapsoVision in the 2nd quarter worth $263,000. Bank of America Corp DE acquired a new position in shares of CapsoVision in the 2nd quarter worth $193,000. Finally, Connective Capital Management LLC acquired a new stake in shares of CapsoVision during the second quarter worth $76,000.
CapsoVision Company Profile
(
Get Free Report)
CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.
The company's principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
